Загрузка...
SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas
Introduction: Prolactinomas are usually benign and respond well to dopamine agonist therapy. However, approximately 20% are resistant, and 10% behave aggressively and persist or recur. Treatment resistance has been associated with ErbB receptor expression, prompting us to conduct a trial of ErbB tar...
Сохранить в:
| Опубликовано в: : | J Endocr Soc |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Endocrine Society
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553305/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-442 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|